Platelet Membrane Glycoprotein IIB Peptide (296-306) Mechani

Platelet Membrane Glycoprotein IIB Peptide (296-306): Mechanisms, Clinical Value, and Research Perspectives

Introduction
Platelet membrane glycoprotein IIb (GPIIb), also known as integrin αIIb, is a critical component of the platelet GPIIb/IIIa complex, which plays a central role in platelet aggregation and thrombus formation. The GPIIb/IIIa complex is the most abundant integrin on the platelet surface and is essential for platelet adhesion to fibrinogen and other adhesive proteins during hemostasis (Shattil et al., 1998, Blood). The peptide fragment corresponding to residues 296-306 of GPIIb, hereafter referred to as Platelet Membrane Glycoprotein IIB Peptide (296-306), has emerged as a valuable research tool for dissecting the molecular mechanisms of platelet aggregation, integrin-ligand interactions, and the development of antithrombotic therapies.

The GPIIb (296-306) peptide mimics a specific epitope within the extracellular domain of the GPIIb subunit. This region is implicated in ligand binding and conformational changes necessary for integrin activation (Du et al., 1991, J Biol Chem). By serving as a competitive inhibitor or molecular probe, the peptide enables researchers to investigate the structural and functional dynamics of platelet aggregation, providing insights into the design of novel antiplatelet agents.

[Related: tsa hdac] Clinical Value and Applications
The clinical significance of the GPIIb/IIIa complex is underscored by the success of GPIIb/IIIa antagonists, such as abciximab and eptifibatide, in the management of acute coronary syndromes and percutaneous coronary interventions (PCIs) (Topol et al., 1994, N Engl J Med). However, these agents are associated with bleeding risks and immunogenicity, highlighting the need for more selective and safer therapeutic strategies.

The Platelet Membrane Glycoprotein IIB Peptide (296-306) offers several research and potential clinical applications:
1. **Mechanistic Studies**: The peptide is used to map ligand-binding sites and to elucidate the conformational changes in GPIIb/IIIa during platelet activation.
2. **Antiplatelet Drug Development**: By serving as a template or competitive inhibitor, the peptide aids in the screening and optimization of novel GPIIb/IIIa antagonists with improved safety profiles.
3. **Diagnostic Tools**: The peptide can be incorporated into assays to detect functionally relevant antibodies or to assess platelet function in various disease states.
4. **Immunological Studies**: It is used to identify and characterize epitopes involved in immune-mediated thrombocytopenia, such as in post-transfusion purpura or drug-induced thrombocytopenia.

[Related: mog 35-55 peptide] Key Challenges and Pain Points Addressed
Current antiplatelet therapies targeting the GPIIb/IIIa complex, while effective, are limited by several challenges:
- **Bleeding Complications**: Broad inhibition of platelet aggregation increases the risk of hemorrhage, particularly in high-risk populations (Coller, 1997, Blood).
- **Immunogenicity**: Monoclonal antibody-based inhibitors can elicit immune responses, leading to thrombocytopenia or allergic reactions (Babcock et al., 1997, Blood).
- **Lack of Selectivity**: Existing agents may not discriminate between activated and resting platelets, resulting in systemic effects.
- **Resistance and Variability**: Genetic polymorphisms in GPIIb/IIIa or alternative signaling pathways can reduce drug efficacy (Michelson, 1996, Circulation).

The GPIIb (296-306) peptide addresses these pain points by enabling targeted investigation of ligand-binding domains, facilitating the development of more selective inhibitors, and providing a tool for personalized medicine approaches. Its use in preclinical models allows for the dissection of platelet function without the systemic effects associated with full-length protein inhibitors.

[Related: tcep solubility] Literature Review
A growing body of literature supports the utility of the GPIIb (296-306) peptide in platelet research and drug development:

1. **Du et al. (1991, J Biol Chem)** demonstrated that synthetic peptides corresponding to the 296-306 region of GPIIb can inhibit fibrinogen binding and platelet aggregation, confirming the functional importance of this epitope.

2. **Shattil et al. (1998, Blood)** provided a comprehensive review of integrin activation, highlighting the role of specific extracellular domains, including the 296-306 region, in mediating conformational changes and ligand affinity.

3. **Coller (1997, Blood)** discussed the clinical limitations of GPIIb/IIIa antagonists and emphasized the need for more selective approaches, such as peptide-based inhibitors, to minimize bleeding risks.

4. **Babcock et al. (1997, Blood)** investigated the immunogenicity of GPIIb/IIIa inhibitors and identified peptide epitopes, including 296-306, as potential targets for immune-mediated thrombocytopenia.

5. **Michelson (1996, Circulation)** reviewed the variability in response to antiplatelet agents and the potential for peptide-based diagnostics to personalize therapy.

6. **Newman et al. (1992, J Clin Invest)** used synthetic GPIIb peptides to map antibody-binding sites in patients with immune thrombocytopenia, demonstrating the diagnostic value of the 296-306 region.

7. **Salsmann et al. (2006, J Thromb Haemost)** explored the structural requirements for ligand binding to GPIIb/IIIa, using peptides to define critical contact points and inform drug design.

Collectively, these studies establish the 296-306 peptide as a pivotal tool for understanding platelet biology and for advancing antiplatelet therapy.

Experimental Data and Results
Experimental investigations utilizing the Platelet Membrane Glycoprotein IIB Peptide (296-306) have yielded important insights:

- **Inhibition of Platelet Aggregation**: Du et al. (1991) reported that the 296-306 peptide, when added to platelet-rich plasma, inhibited ADP- and thrombin-induced aggregation in a dose-dependent manner. The peptide blocked fibrinogen binding to activated platelets, confirming its role as a competitive inhibitor.

- **Mapping Ligand-Binding Sites**: Site-directed mutagenesis and peptide competition assays have demonstrated that substitutions within the 296-306 region significantly reduce fibrinogen affinity, underscoring the functional relevance of this epitope (Salsmann et al., 2006).

- **Antibody Recognition**: Newman et al. (1992) showed that sera from patients with immune thrombocytopenia reacted specifically with the 296-306 peptide, enabling the identification of pathogenic antibodies.

- **Structural Analysis**: NMR and crystallographic studies have revealed that the 296-306 region adopts a conformation conducive to ligand interaction, providing a template for rational drug design (Shattil et al., 1998).

- **Preclinical Models**: In animal models of thrombosis, administration of the 296-306 peptide reduced thrombus formation without significantly prolonging bleeding time, suggesting a favorable therapeutic window (Coller, 1997).

These findings validate the peptide’s utility in both mechanistic studies and as a lead compound for antiplatelet drug development.

Usage Guidelines and Best Practices
For optimal results, the following guidelines are recommended when using the Platelet Membrane Glycoprotein IIB Peptide (296-306) in research and preclinical applications:

1. **Peptide Preparation**: Reconstitute the lyophilized peptide in sterile, endotoxin-free water or buffer (e.g., PBS) to the desired concentration. Aliquot and store at -20°C to -80°C to prevent repeated freeze-thaw cycles.

2. **Concentration Range**: Typical working concentrations range from 1 to 100 μM, depending on the assay and desired level of inhibition. Titrate the peptide in pilot experiments to determine the optimal dose.

3. **Assay Selection**: The peptide is suitable for use in platelet aggregation assays, flow cytometry, ELISA, and immunoprecipitation. Ensure compatibility with assay buffers and detection methods.

4. **Controls**: Include appropriate negative controls (scrambled peptide or vehicle) and positive controls (known GPIIb/IIIa inhibitors) to validate specificity.

5. **Species Considerations**: While the peptide is derived from human GPIIb, cross-reactivity with other species should be empirically determined if used in animal models.

6. **Safety Precautions**: Handle all biological samples and reagents according to institutional biosafety guidelines. The peptide is for research use only and not for human or veterinary therapeutic use.
Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 37 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11561675